Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results
Journal of Acquired Immune Deficiency Syndromes, Volume 69, No. 3, Year 2015
Notification
URL copied to clipboard!
Description
Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Authors & Co-Authors
Gallant, Joel E.
Unknown Affiliation
Koenig, Ellen
Dominican Republic, Santo Domingo
Instituto Dominicano de Estudios Virologicos Idev
Andrade-Villanueva, Jaime Federico
Mexico, Guadalajara
Hospital Civil de Guadalajara
Chetchotisakd, Ploenchan
Thailand, Khon Kaen
Khon Kaen University
DeJesus, Edwin
United States, Orlando
Orlando Immunology Center
Antúnes, Francisco
Portugal, Lisbon
Faculdade de Medicina, Universidade de Lisboa
Arastéh, Keikawus N.
Germany, Berlin
Vivantes Auguste-viktoria-klinikum
Rizzardini, Giuliano
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Fehr, Jan Sven
Switzerland, Zurich
Universität Zürich
Cao, Huyen
United States, Foster City
Gilead Sciences Incorporated
Szwarcberg, Javier
United States, Foster City
Gilead Sciences Incorporated
Statistics
Citations: 28
Authors: 11
Affiliations: 9
Identifiers
Doi:
10.1097/QAI.0000000000000598
ISSN:
15254135
Research Areas
Disability
Infectious Diseases